A retrospective cohort of 335 predominantly frozen embryo transfer cycles found identical clinical pregnancy rates with ...
Seaport Therapeutics offers CNS upside with Glyph technology, solid cash runway, and key Phase 2b data ahead. Read more on ...
Acute viral tonsillitis is a common childhood condition, and high-quality randomized evidence on the efficacy of individualized homeopathic medicines (IHMs) remains limited. This single-center ...
A one-season field study in Guangxi found that alternating sugarcane rows among peanut shifted rhizosphere fungal taxa and ...
Anthropic has acquired a one-person drug discovery company.On October 27, 2026, Anthropic, the developer of Claude, announced ...
Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its ...
The programmer of 2031 may rarely write code. Here's how AI agents could reshape software engineering, developer jobs, and code reviews.
Biomarker Stratification Methodology in the ALSTARS Trial to Minimize the Impact of Heterogeneity in ALS Clinical Tria ...
SELLAS Life Sciences' Phase 3 REGAL trial reached 80 deaths for final analysis, triggering a 18% stock drop despite milestone achievement.
Operator: Greetings, and welcome to ClearPoint Neuro Third Quarter 2026 Financial Results Conference Call. [Operator ...
Viking Therapeutics reported a wider-than-expected third-quarter loss as spending accelerated across its obesity pipeline, ...
PALI-2108 is an investigational, gut-activated, once-daily oral PDE4 inhibitor prodrug designed for sustained exposure and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results